Free Trial

CME Group (CME) Stock Forecast & Price Target

CME Group logo
$263.69 +2.15 (+0.82%)
As of 04:00 PM Eastern

CME Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
4
Hold
7
Buy
5

Based on 16 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 4 have given a sell rating, 7 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for CME.

Consensus Price Target

$247.47
-6.15% Downside
According to the 16 analysts' twelve-month price targets for CME Group, the average price target is $247.47. The highest price target for CME is $301.00, while the lowest price target for CME is $187.00. The average price target represents a forecasted downside of -6.15% from the current price of $263.69.
Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

Sign Up

CME Analyst Ratings Over Time

TypeCurrent Forecast
4/14/24 to 4/14/25
1 Month Ago
3/15/24 to 3/15/25
3 Months Ago
1/15/24 to 1/14/25
1 Year Ago
4/15/23 to 4/14/24
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
7 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
6 Hold rating(s)
Sell
4 Sell rating(s)
4 Sell rating(s)
4 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$247.47$238.93$229.27$215.70
Forecasted Upside-6.15% Downside-7.63% Downside-1.06% Downside2.96% Upside
Consensus Rating
Hold
Reduce
Reduce
Hold
Remove Ads

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CME Group Stock vs. The Competition

TypeCME GroupFinance CompaniesS&P 500
Consensus Rating Score
2.13
2.53
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-6.15% Downside39.42% Upside25.87% Upside
News Sentiment Rating
Positive News

See Recent CME News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/11/2025Oppenheimer
3 of 5 stars
Owen Lau
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$269.00 ➝ $279.00+5.97%
4/8/2025Piper Sandler
2 of 5 stars
Patrick Moley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$275.00 ➝ $283.00+12.14%
4/8/2025Morgan Stanley
3 of 5 stars
 UpgradeEqual Weight ➝ Overweight$301.00+19.27%
4/7/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Benjamin Budish
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$263.00 ➝ $279.00+9.07%
4/3/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ashish Sabadra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$269.00 ➝ $269.00-0.64%
4/2/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Craig Siegenthaler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetUnderperform ➝ Underperform$200.00 ➝ $219.00-16.64%
3/17/2025Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
H. Engel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/10/2025Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick O'Shaughnessy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$287.00+12.74%
2/14/2025Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kyle Voigt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Perform ➝ Market Perform$256.00 ➝ $257.00+3.64%
2/13/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kenneth Worthington
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetUnderweight ➝ Underweight$209.00 ➝ $212.00-15.54%
1/6/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Allen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$255.00 ➝ $250.00+7.53%
11/11/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$227.00 ➝ $226.00-0.14%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Clinch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$244.00+10.04%
10/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$195.00 ➝ $198.00-11.89%
9/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Katz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$221.00+1.60%
4/25/2024Rosenblatt Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell ➝ Sell$185.00 ➝ $187.00-12.04%
3/6/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$225.00 ➝ $245.00+12.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:29 PM ET.


Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, April 7, 2025. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CME Group Inc.:

  • The recent increase in the quarterly dividend to $1.15 reflects CME Group Inc.'s strong financial health and commitment to returning value to shareholders, with a dividend payout ratio of 51.71% indicating a balanced approach to profit distribution.
  • CME Group Inc. has a solid market capitalization of $91.70 billion, which signifies its stability and potential for growth in the financial services sector.
  • The current stock price of $254.46 positions CME Group Inc. favorably within its 52-week range, suggesting resilience and potential for appreciation given its 52-week high of $273.42.
  • Analysts have a consensus rating of "Hold" with a price target of $241.53, indicating that while there may not be immediate bullish sentiment, the stock is viewed as stable with potential for future growth.
  • Recent institutional investments, including a significant stake acquired by Resona Asset Management Co. Ltd., demonstrate confidence in CME Group Inc.'s future performance, as institutional investors often conduct thorough analyses before making large investments.

CME Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CME Group Inc. for these reasons:

  • Despite the positive outlook, four analysts have rated CME Group Inc. with a sell rating, indicating some skepticism about its short-term performance and potential risks in the market.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 26.31, which may suggest that it is overvalued compared to its earnings, potentially limiting upside for new investors.
  • With a beta of 0.53, CME Group Inc. is less volatile than the market, which may appeal to conservative investors but could also mean limited growth during bullish market conditions.
  • The company has a return on equity of 13.62%, which, while positive, may not be as high as some investors expect from leading firms in the financial services sector, indicating room for improvement.
  • Recent reports show that some analysts have downgraded their ratings, with Bank of America giving an "underperform" rating, which could signal potential challenges ahead for the company.

CME Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $247.47, with a high forecast of $301.00 and a low forecast of $187.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 4 sell ratings, 7 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.

According to analysts, CME Group's stock has a predicted downside of -6.15% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 3 upgrades by analysts.

Analysts like CME Group less than other "finance" companies. The consensus rating for CME Group is Hold while the average consensus rating for "finance" companies is Moderate Buy. Learn more on how CME compares to other companies.


This page (NASDAQ:CME) was last updated on 4/14/2025 by MarketBeat.com Staff
From Our Partners